Holen Sie sich die Stockscreener-App
4.20
5.83%
-0.26
Handel nachbörslich:
4.12
-0.08
-1.90%
Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten
PRLD Q1 2026 Earnings: EPS Beat Drives Strong Stock ReactionEPS Growth Rate - newsline.com
[Form 4] Prelude Therapeutics Inc Insider Trading Activity - Stock Titan
Director at Prelude Therapeutics (PRLD) awarded 38,000 stock options - Stock Titan
Prelude Therapeutics (PRLD) director receives 38,000 stock options at $3.94 strike - Stock Titan
PRLD: All director, auditor, and executive compensation proposals were approved by shareholder vote - TradingView
PRLD: All proposals passed, directors elected, auditor ratified, and no shareholder questions submitted - TradingView
PRLD Technical Analysis | Trend, Signals & Chart Patterns | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill
Prelude Therapeutics Rises Pre-Market With Focus on Two Cancer Drugs - Bez Kabli
Prelude Therapeutics Reports Earnings and Advances Precision Oncology Pipeline - asatunews.co.id
Prelude Therapeutics Reports First Quarter Financial Results and Pipeline Expansion - HarianBasis.co
Goldman Sachs Initiates Coverage on Prelude Therapeutics: What It Could Mean for InvestorsEPS Growth Report - newsline.com
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD) - Yahoo Finance
PRLD Stock Price, Quote & Chart | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill
Prelude Therapeutics Drops 5.5% as Biotech Sector Faces Headwinds – Key Support Levels in FocusBollinger Squeeze - The Legal Advocate
Prelude Therapeutics (PRLD) Extends Gains: Support Holds, Resistance in FocusFear Greed Index - The Legal Advocate
PRLD Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesOne-Time Gain Impact - newsline.com
Prelude Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update - geneonline.com
Prelude Therapeutics: Current Cash Runway Into 2Q 2028 >PRLD - Moomoo
New PROTACs reported in Prelude Therapeutics patent - BioWorld News
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Sahm
Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Goldman Sachs initiates Prelude Therapeutics stock coverage as Early-Stage Biotech - Investing.com India
Prelude Therapeutics (PRLD) price target increased by 11.49% to 7.01 - MSN
Prelude Therapeutics (PRLD) Losses Narrow In Q1 2026 Challenging Bearish Narratives - Sahm
TradingKey - TradingKey
Jefferies raises Prelude Therapeutics stock price target on pipeline progress By Investing.com - Investing.com Australia
Prelude (PRLD) Reports Progress on Strategic Initiatives and Cas - GuruFocus
Prelude Therapeutics Reports Q1 2026 Results, Advances Precision Oncology Pipeline and Extends Cash Runway to 2028 - Minichart
Prelude Therapeutics (NASDAQ:PRLD) Reports Narrower Quarterly Loss, Shares Rise on Cash Runway Extension - ChartMill
Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary - TradingView
Prelude Therapeutics Initiates Phase 1 Study of PRT12396 and Provides R&D Pipeline Update - Quiver Quantitative
Prelude Therapeutics Q1 net loss narrows as expenses fall - TradingView
Prelude Therapeutics (NASDAQ: PRLD) trims Q1 2026 loss and extends cash runway to 2028 - Stock Titan
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Weekly Voice
Prelude Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet - Yahoo Finance
Prelude Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
PRLD Initiates Coverage On Prelude Therapeutics -- Price Target Announced at $9.00 - GuruFocus
D. Boral Capital Initiates Prelude Therapeutics(PRLD.US) With Buy Rating, Announces Target Price $9 - Moomoo
Prelude Therapeutics (PRLD) price target increased by 19.35% to 6.29 - MSN
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer - Yahoo Finance
Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research - MarketBeat
9 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
Prelude Therapeutics (NASDAQ: PRLD) outlines 2026 proxy votes on directors, pay and auditor - Stock Titan
Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Decreases By 22.1% - MarketBeat
HC Wainwright Issues Positive Estimate for PRLD Earnings - MarketBeat
RA Capital reports 7.88M-share Prelude Therapeutics (PRLD) stake - Stock Titan
Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
H.C. Wainwright raises Prelude Therapeutics price target to $8 By Investing.com - Investing.com Canada
PRLD Maintained by HC Wainwright & Co. -- Price Target Raised to $8 - GuruFocus
HC Wainwright Issues Positive Forecast for Prelude Therapeutics (NASDAQ:PRLD) Stock Price - MarketBeat
Thursday’s insider trading: Major buys at Prelude, sells at NuScale - Investing.com
Prelude Therapeutics (NASDAQ:PRLD) Director David Bonita Buys 2,815,315 Shares - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Director Buys $12,499,998.60 in Stock - MarketBeat
Insider Purchase: Director at $PRLD Buys 1,689,189 Shares - Moomoo
Orbimed entities acquire $12.5m in Prelude Therapeutics stock By Investing.com - Investing.com Canada
Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock - Investing.com
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):